| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.007 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.007 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.007 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.098 | 0.008 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.091 | 0.009 |
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.098 | 0.01 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.01 |